- Home
- GCI vs DCTH Comparison
GCI vs DCTH Comparison
Compare GCI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- DCTH
- Stock Information
- Founded
- GCI 1997
- DCTH 1988
- Country
- GCI United States
- DCTH United States
- Employees
- GCI 11700
- DCTH N/A
- Industry
- GCI Newspapers/Magazines
- DCTH Medical/Dental Instruments
- Sector
- GCI Consumer Discretionary
- DCTH Health Care
- Exchange
- GCI Nasdaq
- DCTH Nasdaq
- Market Cap
- GCI 509.6M
- DCTH 630.4M
- IPO Year
- GCI N/A
- DCTH N/A
- Fundamental
- Price
- GCI $3.55
- DCTH $16.21
- Analyst Decision
- GCI Buy
- DCTH Strong Buy
- Analyst Count
- GCI 3
- DCTH 4
- Target Price
- GCI $5.70
- DCTH $24.00
- AVG Volume (30 Days)
- GCI 1.5M
- DCTH 610.5K
- Earning Date
- GCI 05-01-2025
- DCTH 05-08-2025
- Dividend Yield
- GCI N/A
- DCTH N/A
- EPS Growth
- GCI N/A
- DCTH N/A
- EPS
- GCI 0.36
- DCTH N/A
- Revenue
- GCI $2,445,127,000.00
- DCTH $53,850,000.00
- Revenue This Year
- GCI N/A
- DCTH $141.47
- Revenue Next Year
- GCI N/A
- DCTH $49.31
- P/E Ratio
- GCI $9.92
- DCTH N/A
- Revenue Growth
- GCI N/A
- DCTH 1068.87
- 52 Week Low
- GCI $2.55
- DCTH $6.33
- 52 Week High
- GCI $5.93
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- GCI 54.94
- DCTH 58.15
- Support Level
- GCI $3.31
- DCTH $16.02
- Resistance Level
- GCI $3.55
- DCTH $17.29
- Average True Range (ATR)
- GCI 0.14
- DCTH 0.99
- MACD
- GCI -0.02
- DCTH -0.03
- Stochastic Oscillator
- GCI 30.92
- DCTH 49.63
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.